A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Tesevatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Kadmon Corporation
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Dec 2016.
- 29 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 30 Sep 2016.